Pfizer: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, M
- Recall status
- Ongoing (still active)
- Severity
- Class II: could cause temporary or reversible health problems What recall classes mean
- Where sold
- US Nationwide and Puerto Rico
Common questions
- Is Pfizer Levoxyl (levothyroxine sodium tablets USP) tablets 175 mcg 100 tablet recalled?
- Yes. FDA (drug) recalled Pfizer Levoxyl (levothyroxine sodium tablets USP) tablets 175 mcg 100 tablet on 2026-10-28. Recall status: Ongoing (still active).
- What is the hazard?
- Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
- Where was it sold?
- US Nationwide and Puerto Rico
Read the official notice at FDA (drug) →
More recalls
- Pfizer: Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg
- Pfizer: Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25
- bioQuad Life Sciences: OsteoDenx capsules
- Game Changer Products, LLC: 10 Day Forecast Capsules 3200mg
- Eugia US LLC: Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single
The text below is copied from the official FDA (drug) record. If anything differs, the official notice is correct.
- Company / brand
- Pfizer
- Product
- Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.
- Reason / hazard
- Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
- What to do (remedy)
- Classification
- Class II
- Status
- Ongoing
- Distribution / sold at
- US Nationwide and Puerto Rico
- Recall initiated
- 2026-09-29
- Code info
- Lot # 24W06, Exp: 11/30/2026
- Product quantity
- 15,815 100-count bottles
- Voluntary mandated
- Voluntary: Firm initiated
- City
- Manhattan
- State
- NY
- Country
- United States
- Event id
- 99963
Free daily digest + "My products" watchlist